Gene therapy for heart failure: Where do we stand?

Current Cardiology Reports

Volumn 15, Issue 2, 2013, Pages

  Naim, Charbel ^a   Yerevanian, Armen ^a   Hajjar, Roger J ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Adeno associated vectors; Calcium handling; Cardiac gene transfer; Gene therapy; Heart failure; Phospholamban; Sarcoplasmic reticulum; SERCA2a

Indexed keywords

ADENOVIRUS VECTOR; ADENYLATE CYCLASE; BETA 1 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR; CALCIUM CHANNEL; CYTOKINE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; G PROTEIN COUPLED RECEPTOR KINASE 2; LENTIVIRUS VECTOR; NANOPARTICLE; PARVOVIRUS VECTOR; PHOSPHOLAMBAN; PLASMID VECTOR; PROTEIN S 100; RETROVIRUS VECTOR; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE 2A; STROMAL CELL DERIVED FACTOR 1; SUMO 1 PROTEIN; UNCLASSIFIED DRUG; BETA ADRENERGIC RECEPTOR;

ADRENERGIC SYSTEM; ARTERY CATHETERIZATION; ARTICLE; CALCIUM TRANSPORT; CELL PROLIFERATION; CLINICAL TRIAL (TOPIC); DNA METHYLATION; GENE TECHNOLOGY; GENE THERAPY; GENE TRANSFER; HEART FAILURE; HEART MUSCLE CONTRACTILITY; HETEROCHROMATIN; HISTONE MODIFICATION; HUMAN; INTRAMYOCARDIAL INJECTION GENE DELIVERY; MATRIX ATTACHMENT REGION; MOLECULARLY TARGETED THERAPY; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PERCUTANEOUS CORONARY INTERVENTION; PERICARDIAL GENE DELIVERY; PHASE 2 CLINICAL TRIAL (TOPIC); GENE VECTOR; METHODOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW;

GENETIC THERAPY; GENETIC VECTORS; HEART FAILURE; HUMANS; RECEPTORS, ADRENERGIC, BETA; SARCOPLASMIC RETICULUM CALCIUM-TRANSPORTING ATPASES;

MLCS; MLOWN;

EID: 84879308390     PISSN: 15233782     EISSN: 15343170     Source Type: Journal    
DOI: 10.1007/s11886-012-0333-3     Document Type: Article

References (99)

1. Engelhardt S, Hein L, Dyachenkow V, et al. Altered calcium handling is critically involved in the cardiotoxic effects of chronic beta-Adrenergic stimulation. Circulation. 2004;109(9):1154-60. (Pubitemid 38332620)
2. Milano CA, Allen LF, Rockman HA, et al. Enhanced myocardial function in transgenic mice overexpressing the beta 2-Adrenergic receptor. Science. 1994;264(5158):582-6.
3. Maurice JP, Hata JA, Shah AS, et al. Enhancement of cardiac function after adenoviral-mediated in vivo intracoronary beta2-Adrenergic receptor gene delivery. J Clin Invest. 1999;104(1):21-9. (Pubitemid 29534341)
4. Shah AS, Lilly RE, Kypson AP, et al. Intracoronary adenovirusmediated delivery and overexpression of the beta(2)-Adrenergic receptor in the heart: prospects for molecular ventricular assistance. Circulation. 2000;101(4):408-14. (Pubitemid 30067398)
5. Hata JA, Williams ML, Koch WJ. Genetic manipulation of myocardial beta-Adrenergic receptor activation and desensitization. J Mol Cell Cardiol. 2004;37(1):11-21. (Pubitemid 38900524)
6. Raake PW, Vinge LE, Gao E, et al. G protein-coupled receptor kinase 2 ablation in cardiac myocytes before or after myocardial infarction prevents heart failure. Circ Res. 2008;103(4):413-22.
7. Shah AS,White DC, Emani S, et al. In vivo ventricular gene delivery of a beta-Adrenergic receptor kinase inhibitor to the failing heart reverses cardiac dysfunction. Circulation. 2001;103(9):1311-6. (Pubitemid 32221357)
8. Katz MG, Fargnoli AS, Swain JD, et al. AAV6-betaARKct gene delivery mediated by molecular cardiac surgery with recirculating delivery (MCARD) in sheep results in robust gene expression and increased adrenergic reserve. J Thorac Cardiovasc Surg. 2011.
9. Gao MH, Lai NC, Roth DM, et al. Adenylylcyclase increases responsiveness to catecholamine stimulation in transgenic mice. Circulation. 1999;99(12):1618-22. (Pubitemid 29152931)
10. Lai NC, Roth DM, Gao MH, et al. Intracoronary adenovirus encoding adenylyl cyclase VI increases left ventricular function in heart failure. Circulation. 2004;110(3):330-6. (Pubitemid 38955502)
11. Lai NC, Roth DM, Gao MH, et al. Intracoronary delivery of adenovirus encoding adenylyl cyclase VI increases left ventricular function and cAMP-generating capacity. Circulation. 2000;102 (19):2396-401.
12. Gwathmey JK, Copelas L, MacKinnon R, et al. Abnormal intracellular calcium handling in myocardium from patients with endstage heart failure. Circ Res. 1987;61(1):70-6. (Pubitemid 17133480)
13. Hasenfuss G, Reinecke H, Studer R, et al. Relation between myocardial function and expression of sarcoplasmic reticulum Ca (2+)-ATPase in failing and nonfailing human myocardium. Circ Res. 1994;75(3):434-42.
14. Meyer M, Schillinger W, Pieske B, et al. Alterations of sarcoplasmic reticulum proteins in failing human dilated cardiomyopathy. Circulation. 1995;92(4):778-84.
15. Schmidt U, Hajjar RJ, Kim CS, et al. Human heart failure: cAMP stimulation of SR Ca(2+)-ATPase activity and phosphorylation level of phospholamban. Am J Physiol. 1999;277(2 Pt 2):H474-80. (Pubitemid 29415959)
16. Lompre AM, Lambert F, Lakatta EG, Schwartz K. Expression of sarcoplasmic reticulum Ca(2+)-ATPase and calsequestrin genes in rat heart during ontogenic development and aging. Circ Res. 1991;69(5):1380-8.
17. Miyamoto MI, del Monte F, Schmidt U, et al. Adenoviral gene transfer of SERCA2a improves left-ventricular function in aorticbanded rats in transition to heart failure. Proc Natl Acad Sci U S A. 2000;97(2):793-8. (Pubitemid 30070389)
18. del Monte F, Harding SE, Schmidt U, et al. Restoration of contractile function in isolated cardiomyocytes from failing human hearts by gene transfer of SERCA2a. Circulation. 1999;100 (23):2308-11.
19. Kawase Y, Ly HQ, Prunier F, et al. Reversal of cardiac dysfunction after long-Term expression of SERCA2a by gene transfer in a preclinical model of heart failure. J Am Coll Cardiol. 2008;51 (11):1112-9. (Pubitemid 351374774)
20. Sakata S, Lebeche D, Sakata N, et al. Restoration of mechanical and energetic function in failing aortic-banded rat hearts by gene transfer of calcium cycling proteins. J Mol Cell Cardiol. 2007;42 (4):852-61. (Pubitemid 46527593)
21. Sakata S, Lebeche D, Sakata Y, et al. Transcoronary gene transfer of SERCA2a increases coronary blood flow and decreases cardiomyocyte size in a type 2 diabetic rat model. Am J Physiol Heart Circ Physiol. 2007;292(2):H1204-7.
22. Lyon AR, Bannister ML, Collins T, et al. SERCA2a Gene Transfer Decreases SR Calcium Leak and Reduces Ventricular Arrhythmias in a Model of Chronic Heart Failure. Circ Arrhythm Electrophysiol. 2011. Elucidates on the safety of SERCA2a gene transfer.
23. Cutler MJ, Wan X, Laurita KR, et al. Targeted SERCA2a gene expression identifies molecular mechanism and therapeutic target for arrhythmogenic cardiac alternans. Circ Arrhythmia Electrophysiol. 2009;2(6):686-94.
24. del Monte F, Lebeche D, Guerrero JL, et al. Abrogation of ventricular arrhythmias in a model of ischemia and reperfusion by targeting myocardial calcium cycling. Proc Natl Acad Sci U S A. 2004;101(15):5622-7. (Pubitemid 38481206)
25. Prunier F, Kawase Y, Gianni D, et al. Prevention of ventricular arrhythmias with sarcoplasmic reticulum Ca2+ ATPase pump overexpression in a porcine model of ischemia reperfusion. Circulation. 2008;118(6):614-24.
26. Hadri L, Bobe R, Kawase Y, et al. SERCA2a Gene Transfer Enhances eNOS Expression and Activity in Endothelial Cells. Molecular Therapy. 2010. Reveals the role of SERCA2a gene therapy in the treatment of vascular disease.
27. del Monte F, Harding SE, Dec GW, et al. Targeting phospholamban by gene transfer in human heart failure. Circulation. 2002;105 (8):904-7. (Pubitemid 34184564)
28. Kaye DM, Preovolos A, Marshall T, et al. Percutaneous cardiac recirculation-mediated gene transfer of an inhibitory phospholamban peptide reverses advanced heart failure in large animals. J Am Coll Cardiol. 2007;50(3):253-60. (Pubitemid 47031573)
29. Suckau L, Fechner H, Chemaly E, et al. Long-Term cardiactargeted RNA interference for the treatment of heart failure restores cardiac function and reduces pathological hypertrophy. Circulation. 2009;119(9):1241-52.
30. Nicolaou P, Rodriguez P, Ren X, et al. Inducible Expression of Active Protein Phosphatase-1 Inhibitor-1 Enhances Basal Cardiac Function and Protects Against Ischemia/Reperfusion Injury. Circ Res. 2009.
31. Pathak A, Baldwin B, Kranias EG. Key protein alterations associated with hyperdynamic cardiac function: insights based on proteomic analysis of the protein phosphatase 1 inhibitor-1 overexpressing hearts. Hellenic J Cardiol HJC0Hellenike kardiologike epitheorese. 2007;48(1):30-6. (Pubitemid 47621109)
32. Pathak A, del Monte F, Zhao W, et al. Enhancement of cardiac function and suppression of heart failure progression by inhibition of protein phosphatase 1. Circ Res. 2005;96(7):756-66. (Pubitemid 40559515)
33. Most P, Pleger ST, Völkers M, et al. Cardiac adenoviral S100A1 gene delivery rescues failing myocardium. J Clin Invest. 2004;114:1550-63. (Pubitemid 40385546)
34. Pleger ST, Most P, Boucher M, et al. Stable myocardial-specific AAV6-A1 gene therapy results in chronic functional heart failure rescue. Circulation. 2007;115(19):2506-15. (Pubitemid 46763224)
35. Most P, Koch WJ. S100A1: a calcium-modulating inotropic prototype for future clinical heart failure therapy. Futur Cardiol. 2007;3(1):5-11. (Pubitemid 46157665)
36. Kho C, Lee A, Jeong D, et al. SUMO1-dependent modulation of SERCA2a in heart failure. Nature. 2011;477(7366):601-5. Insight on new therapeutic targets for heart failure.
37. Ghadge SK, Muhlstedt S, Ozcelik C, Bader M. SDF-1alpha as a therapeutic stem cell homing factor in myocardial infarction. Pharmacol Ther. 2011;129(1):97-108.
38. Kawase Y, Ladage D, Hajjar RJ. Rescuing the failing heart by targeted gene transfer. J Am Coll Cardiol. 2011;57(10):1169-80.
39. Pyo RT, Sui J, Dhume A, et al. CXCR4 modulates contractility in adult cardiac myocytes. J Mol Cell Cardiol. 2006;41(5):834-44. (Pubitemid 44635574)
40. Chen J, Chemaly E, Liang L, et al. Effects of CXCR4 gene transfer on cardiac function after ischemia-reperfusion injury. Am J Pathol. 2010;176(4):1705-15.
41. LaRocca TJ, Schwarzkopf M, Altman P, et al. beta2-Adrenergic receptor signaling in the cardiac myocyte is modulated by interactions with CXCR4. J Cardiovasc Pharmacol. 2010;56(5):548-59.
42. Harraghy N, Gaussin A, Mermod N. Sustained transgene expression using MAR elements. Curr gene Ther. 2008;8(5):353-66.
43. Girod PA, Nguyen DQ, Calabrese D, et al. Genome-wide prediction of matrix attachment regions that increase gene expression in mammalian cells. Nat Meth. 2007;4(9):747-53. (Pubitemid 47338170)
44. Ehrhardt A, Peng PD, Xu H, et al. Optimization of cis-Acting elements for gene expression from nonviral vectors in vivo. Hum gene Ther. 2003;14(3):215-25. (Pubitemid 36423441)
45. Argyros O, Wong SP, Fedonidis C, et al. Development of S/MAR minicircles for enhanced and persistent transgene expression in the mouse liver. J Mol Med (Berl). 2011;89(5):515-29.
46. Yockman JW, Kastenmeier A, Erickson HM, et al. Novel polymer carriers and gene constructs for treatment of myocardial ischemia and infarction. J Contr Release Official J Contr Release Soc. 2008;132(3):260-6.
47. Wasala NB, Shin JH, Duan D. The evolution of heart gene delivery vectors. J Gene Med. 2011;13(10):557-65.
48. Themis M, May D, Coutelle C, Newbold RF. Mutational effects of retrovirus insertion on the genome of V79 cells by an attenuated retrovirus vector: implications for gene therapy. Gene Ther. 2003;10(19):1703-11. (Pubitemid 37069498)
49. Fischer A, Hacein-Bey-Abina S, Cavazzana-Calvo M. 20 years of gene therapy for SCID. Nat Immunol. 2010;11(6):457-60.
50. Hacein-Bey-Abina S, Von Kalle C, Schmidt M, et al. LMO2-Associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science. 2003;302(5644):415-9. (Pubitemid 37296260)
51. Cavazzana-Calvo M, Hacein-Bey S, de Saint Basile G, et al. Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science. 2000;288(5466):669-72. (Pubitemid 30241569)
52. Kraunus J, Schaumann DH, Meyer J, et al. Self-inactivating retroviral vectors with improved RNA processing. Gene Ther. 2004;11 (21):1568-78. (Pubitemid 39433477)
53. Vodicka MA. Determinants for lentiviral infection of non-dividing cells. Somat Cell Mol Genet. 2001;26(1-6):35-49.
54. Levine BL, Humeau LM, Boyer J, et al. Gene transfer in humans using a conditionally replicating lentiviral vector. Proc Natl Acad Sci U S A. 2006;103(46):17372-7. (Pubitemid 44788976)
55. Kohn DB. Lentiviral vectors ready for prime-Time. Nat Biotechnol. 2007;25(1):65-6. (Pubitemid 46087903)
56. Mortellaro A, Hernandez RJ, Guerrini MM, et al. Ex vivo gene therapy with lentiviral vectors rescues adenosine deaminase (ADA)-deficient mice and corrects their immune and metabolic defects. Blood. 2006;108(9):2979-88.
57. Matyas L, Schulte KL, Dormandy JA, et al. Arteriogenic gene therapy in patients with unreconstructable critical limb ischemia: a randomized, placebo-controlled clinical trial of adenovirus 5-delivered fibroblast growth factor-4. Hum Gene Ther. 2005;16 (10):1202-11. (Pubitemid 41443712)
58. Tongers J, Roncalli JG, Losordo DW. Therapeutic angiogenesis for critical limb ischemia: microvascular therapies coming of age. Circulation. 2008;118(1):9-16.
59. Raper SE, Chirmule N, Lee FS, et al. Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. Mol Genet Metab. 2003;80(1-2):148-58. (Pubitemid 37272241)
60. Asokan A, Conway JC, Phillips JL, et al. Reengineering a receptor footprint of adeno-Associated virus enables selective and systemic gene transfer to muscle. Nat Biotechnol. 2010;28(1):79-82.
61. Wang J, Faust SM, Rabinowitz JE. The next step in gene delivery: molecular engineering of adeno-Associated virus serotypes. J Mol Cell Cardiol. 2011;50(5):793-802.
62. Mitchell AM, Nicolson SC, Warischalk JK, Samulski RJ. AAV's anatomy: roadmap for optimizing vectors for translational success. Curr Gene Ther. 2010;10(5):319-40.
63. LiW, Asokan A,Wu Z, et al. Engineering and selection of shuffled AAV genomes: a new strategy for producing targeted biological nanoparticles. Mol Ther: J Am SocGene Ther. 2008;16(7):1252-60. (Pubitemid 351866056)
64. Ying Y, Muller OJ, Goehringer C, et al. Heart-Targeted adenoassociated viral vectors selected by in vivo biopanning of a random viral display peptide library. Gene Ther. 2010;17(8):980-90.
65. Jaski BE, Jessup ML, Mancini DM, et al. Calcium upregulation by percutaneous administration of gene therapy in cardiac disease (CUPID Trial), a first-in-human phase 1/2 clinical trial. J Card Fail. 2009;15(3):171-81. Ascertains the critical role of SERCA2a in the pathogenesis of heart failure.
66. Boecker W, Bernecker OY, Wu JC, et al. Cardiac-specific gene expression facilitated by an enhanced myosin light chain promoter. Mol Imaging. 2004;3(2):69-75.
67. Prasad KM, Xu Y, Yang Z, et al. Robust cardiomyocyte-specific gene expression following systemic injection of AAV: in vivo gene delivery follows a Poisson distribution. Gene Ther. 2011;18(1):43-52.
68. Ruan H, Su H, Hu L, et al. A hypoxia-regulated adeno-Associated virus vector for cancer-specific gene therapy. Neoplasia (New York, NY). 2001;3(3):255-63. (Pubitemid 32747574)
69. Su H, Kan YW. Adeno-Associated viral vector-delivered hypoxiainducible gene expression in ischemic hearts. Meth Mol Biol (Clifton, NJ). 2007;366:331-42. (Pubitemid 350183485)
70. Vanrell L, Di Scala M, Blanco L, et al. Development of a liverspecific Tet-on inducible system for AAV vectors and its application in the treatment of liver cancer. Mol Ther J Am Soc Gene Ther. 2011;19(7):1245-53.
71. Ye X, Rivera VM, Zoltick P, et al. Regulated delivery of therapeutic proteins after in vivo somatic cell gene transfer. Science. 1999;283(5398):88- 91. (Pubitemid 29045765)
72. Parsa CJ, Reed RC, Walton GB, et al. Catheter-mediated subselective intracoronary gene delivery to the rabbit heart: introduction of a novel method. J Gene Med. 2005;7(5):595-603. (Pubitemid 40744525)
73. Hayase M, Del Monte F, Kawase Y, et al. Catheter-based antegrade intracoronary viral gene delivery with coronary venous blockade. Am J Physiol Heart Circ Physiol. 2005;288(6):H2995-3000. (Pubitemid 40720685)
74. Beeri R, Chaput M, Guerrero JL, et al. Gene delivery of sarcoplasmic reticulum calcium ATPase inhibits ventricular remodeling in ischemic mitral regurgitation. Circ Heart Fail. 2010;3(5):627-34.
75. Byrne MJ, Power JM, Preovolos A, et al. Recirculating cardiac delivery of AAV2/1SERCA2a improves myocardial function in an experimental model of heart failure in large animals. Gene Ther. 2008;15(23):1550-7.
76. Mariani JA, Smolic A, Preovolos A, et al. Augmentation of left ventricular mechanics by recirculation-mediated AAV2/1-SERCA2a gene delivery in experimental heart failure. Eur J Hear Fail. 2011;13 (3):247-53.
77. Sasano T, Kikuchi K, McDonald AD, et al. Targeted highefficiency, homogeneous myocardial gene transfer. J Mol Cell Cardiol. 2007;42(5):954-61. (Pubitemid 46678029)
78. Ryden L, Tadokoro H, Sjoquist PO, et al. Pharmacokinetic analysis of coronary venous retroinfusion: a comparison with anterograde coronary artery drug administration using metoprolol as a tracer. J Am Coll Cardiol. 1991;18(2):603-12.
79. Karagueuzian HS, Ohta M, Drury JK, et al. Coronary venous retroinfusion of procainamide: a new approach for the management of spontaneous and inducible sustained ventricular tachycardia during myocardial infarction. J Am Coll Cardiol. 1986;7 (3):551-63. (Pubitemid 16164382)
80. Su LT, Gopal K, Wang Z, et al. Uniform scale-independent gene transfer to striated muscle after transvenular extravasation of vector. Circulation. 2005;112(12):1780-8. (Pubitemid 41368154)
81. Boekstegers P, von Degenfeld G, Giehrl W, et al. Myocardial gene transfer by selective pressure-regulated retroinfusion of coronary veins. Gene Ther. 2000;7(3):232-40. (Pubitemid 30113772)
82. Raake P, von Degenfeld G, Hinkel R, et al. Myocardial gene transfer by selective pressure-regulated retroinfusion of coronary veins: comparison with surgical and percutaneous intramyocardial gene delivery. J Am Coll Cardiol. 2004;44(5):1124-9. (Pubitemid 39165150)
83. Hou D, Maclaughlin F, Thiesse M, et al. Widespread regional myocardial transfection by plasmid encoding Del-1 following retrograde coronary venous delivery. Cathet Cardiovasc Interv Official J Soc Card Angiography Interv. 2003;58(2):207-11. (Pubitemid 36159567)
84. Davidson MJ, Jones JM, Emani SM, et al. Cardiac gene delivery with cardiopulmonary bypass. Circulation. 2001;104(2):131-3. (Pubitemid 32655825)
85. White JD, Thesier DM, Swain JB, et al. Myocardial gene delivery using molecular cardiac surgery with recombinant adeno-Associated virus vectors in vivo. Gene Ther. 2011;18 (6):546-52.
86. Grossman PM, Han Z, Palasis M, et al. Incomplete retention after direct myocardial injection. Cathet Cardiovasc Interv Official J Soc Card Angiography Interv. 2002;55(3):392-7. (Pubitemid 34204886)
87. Bish LT, Sleeper MM, Brainard B, et al. Percutaneous transendocardial delivery of self-complementary adeno-Associated virus 6 achieves global cardiac gene transfer in canines. Mol Ther J Am Soc Gene Ther. 2008;16(12):1953-9.
88. French BA, Mazur W, Geske RS, Bolli R. Direct in vivo gene transfer into porcine myocardium using replication-deficient adenoviral vectors. Circulation. 1994;90(5):2414-24.
89. Gepstein L, Hayam G, Ben-Haim SA. A novel method for nonfluoroscopic catheter-based electroanatomical mapping of the heart. In vitro and in vivo accuracy results. Circulation. 1997;95 (6):1611-22. (Pubitemid 27142822)
90. Sanborn TA, Hackett NR, Lee LY, et al. Percutaneous endocardial transfer and expression of genes to the myocardium utilizing fluoroscopic guidance. Cathet Cardiovasc Interv Official J Soc Card Angiography Interv. 2001;52(2):260-6. (Pubitemid 32115147)
91. Baklanov DV, de Muinck ED, Simons M, et al. Live 3D echo guidance of catheter-based endomyocardial injection. Cathet Cardiovasc Interv Official J Soc Card Angiography Interv. 2005;65 (3):340-5. (Pubitemid 40898175)
92. Lederman RJ, Guttman MA, Peters DC, et al. Catheter-based endomyocardial injection with real-Time magnetic resonance imaging. Circulation. 2002;105(11):1282-4. (Pubitemid 34260416)
93. Fromes Y, Salmon A, Wang X, et al. Gene delivery to the myocardium by intrapericardial injection. Gene Ther. 1999;6(4):683-8. (Pubitemid 29192678)
94. Ladage D, Turnbull IC, Ishikawa K, et al. Delivery of gelfoamenabled cells and vectors into the pericardial space using a percutaneous approach in a porcine model. Gene Ther. 2011;18 (10):979-85.
95. Lamping KG, Rios CD, Chun JA, et al. Intrapericardial administration of adenovirus for gene transfer. Am J Physiol. 1997;272 (1 Pt 2):H310-7.
96. Roques C, Salmon A, Fiszman MY, et al. Intrapericardial administration of novel DNA formulations based on thermosensitive Poloxamer 407 gel. Int J Pharm. 2007;331(2):220-3. (Pubitemid 46216676)
97. Boulanger B, Yuan Z, Flessner M, et al. Pericardial fluid absorption into lymphatic vessels in sheep. Microvasc Res. 1999;57 (2):174-86. (Pubitemid 29393294)
98. Hajjar RJ, Zsebo K, Deckelbaum L, et al. Design of a phase 1/2 trial of intracoronary administration of AAV1/SERCA2a in patients with heart failure. J Card Fail. 2008;14(5):355-67. (Pubitemid 351756538)
99. Jessup M, Greenberg B, Mancini D, et al. Calcium Upregulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID): a phase 2 trial of intracoronary gene therapy of sarcoplasmic reticulum Ca2 + -ATPase in patients with advanced heart failure. Circulation. 2011;124(3):304-13.